This cancer specialist is looking to defeat the KRAS mutation.
News & Analysis: Cardiff Oncology, Inc.
The biotech presented data from an early-stage study of its experimental colorectal cancer drug.
Here's why shares of these drugmakers seem unstoppable this year.
An analyst's bullish outlook sent the biotech stock soaring.